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Abstract
Background: Analysis of cerebrospinal fluid (CSF) to
discriminate between benign and malignant condi-
tions is of fundamental importance for the physician
and the patient because of the differential therapeutic
options and resulting morbidity and mortality. Most
human tumours demonstrate increased telomerase
activity (TA). Recent technical advances in the detec-
tion of TA allow for sensitive and specific detection
within 4 h. Thus, the detection of TA is suitable for
routine clinical testing.
Methods: This study examines TA in cellular proteins
in CSF from 111 patients compared to cytomorpho-
logical and laboratory examination.
Results: A positive result for TA in cellular proteins of
CSF was correlated significantly with Meningeosis
neoplastica, but not with non-malignant conditions.
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Telomerase was not detected in CSF supernatant,
despite positive results in cellular proteins from iden-
tical patients. Furthermore, a 48-h time delay during
the pre-analytic processing is not critical for detection
of TA detection in native CSF when stored at room
temperature.
Conclusions: We conclude that TA is a promising
marker for the detection of Meningeosis neoplastica
and warrants further study.
Clin Chem Lab Med 2009;47:1271–6.
Keywords: cerebrospinal fluid; Meningeosis neoplas-
tica; real-time quantitative telomere repeat amplifica-
tion protocol; telomerase activity.
Introduction
Cytological analysis of cerebrospinal fluid (CSF) is the
standard procedure for the diagnosis of meningitis or
Meningeosis neoplastica. The incidence of Meningeo-
sis neoplastica diagnosed by cytology in a large non-
selected series of 5951 specimens by Prayson and
Fischler (1) was 5% in adults and 8% in paediatric
patients. Despite the low incidence of Meningeosis
neoplastica, discrimination between non-malignant
and malignant cytology is of vital importance for the
patient due to fundamentally differential therapeutic
regimens (anti-infective, immunosuppressive or no
therapy vs. anti-neoplastic therapy). Leptomeningeal
involvement is present in about 6% of patients diag-
nosed with acute lymphatic leukaemia (2) and devel-
ops in about 5% of patients with solid tumours (3, 4).
In spite of substantial advances in prophylaxis and
therapy, the detection of Meningeosis neoplastica
usually requires an intensification of anti-neoplastic
therapy and predicts an unfavourable outcome in
patients resulting from increased disease and therapy
related morbidity and mortality (5, 6). Alternative
diagnostic technologies including gadolinium imag-
ing (7) or mass spectroscopy (8) are inferior to CSF
cytology. For lymphoid neoplasms, multiparameter
flow cytometric analysis of CSF (9, 10) may be helpful
as an adjunct to cytology, which remains the gold
standard for the diagnosis of Meningeosis neoplastica
(11).
The enzyme telomerase consists of a catalytic pro-
tein subunit human telomerase reverse transcriptase
(hTert) and a ribonucleic acid (RNA) template human
telomerase RNA (hTr). Telomerase is capable of telo-
mere repeat elongation in vivo involving a unique
reverse transcriptase activity, able to regulate telo-
mere length in vivo (12). However, functionally active
telomerase is restricted to embryonic stem cells (13),
germ line cells (14), rarely in differentiated cells like
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Figure 1 Correlation of telomerase activity (TA) to cell num-
ber in serially diluted HEK293 cells.
There was a linear correlation between detection of TA and
the HEK293 cell number in the range of 1000-8 HEK293 cells
(R2s0.99).
lymphocytes or adult haematopoietic stem cells
(15–17) and, notably, in neoplastic cells. Because
telomeres progressively shorten with each cellular
division as a sign of replicative senescence (18), sta-
bilisation of telomeres by activation of telomerase is
presumed to be a fundamental mechanism for indef-
inite proliferation in neoplasia. Up to 90% of human
tumours express telomerase (19), whereas the re-
maining tumours have developed alternative mecha-
nisms to stabilize their telomeres (20).
Here, we exploited the fact that neoplastic cells are
characterised by highly active telomerase in order to
facilitate a more rapid diagnoses of Meningeosis neo-
plastica. With the development of a fast and reliable
real-time polymerase chain reaction (PCR) based
methodology wreal-time quantitative telomere repeat
amplification protocol (RQ-Trap) assay as reported by
Wege et al. (21)x the detection of telomerase activa-
tion may be potentially useful in clinical practice. We
have previously shown that telomerase activity (TA)
can be measured in lymphoblasts from peripheral
blood or CSF using the RQ-Trap protocol (16). The
present study was designed to assess the feasibility
and diagnostic accuracy of measuring TA on a routine
basis for the detection of Meningeosis neoplastica in
diagnostic CSF.
Materials and methods
The study was approved by the Local Ethics Committee and
all study participants gave written informed consent. CSF
was drawn from patients undergoing routine lumbar punc-
ture and was centrifuged at 800 g for 5 min, within 30 min
following collection of CSF. The cell pellet and the super-
natant were stored at –808C until further analysis. Samples
for TA assays were extracted following standard protocols
(22). Cytological examination was performed by an expert
cytopathologist who was not aware of other laboratory test
results.
Telomerase activity
TA was quantified under real-time PCR conditions utilizing
the RQ-Trap procedure (Lightcycler instrument, Roche,
Mannheim, Germany) as reported by Wege et al. (21) with
minor modifications. In brief, duplicates of protein extracts
from 1000 cells or CSF supernatant were mixed with 0.1 mg
of Primer TS (template) and 0.05 mg Primer ACX (23) in
20 mL Lightcycler Fast Start SYBR Green PCR Master Mix
(Roche, Mannheim, Germany) containing 1.5 mM MgCl2. The
mixture was incubated at 308C for 30 min to allow template
elongation by TA. Immediately following transfer to the
Lightcycler instrument, telomerase was heat-inactivated and
hotstart DNA polymerase activated by incubation at 958C for
10 min. Thirty-six cycles of amplification were performed
with 20 s denaturation at 958C, annealing for 30 s at 608C,
and elongation for 50 s at 728C. TA was displayed as relative
TA to a standard of 1000 HEK293 cells. A standard titration
curve of HEK293 cells was established using 0–1000 cells to
ensure linearity of the assay. A positive signal was obtained
with a minimal dilution of 8/1000 HEK293 cells in repetitive
experiments. A positive result of the RQ-Trap assay was
assumed when the sample’s Ct value was three standard
deviations (SD) above the mean Ct value obtained with
repetitive measures of lysed and heat inactivated HEK293
cells. Therefore, the cut-off for a positive test result was
defined as a relative TA of 1% (equally to a TA of 10/1000
HEK293 cells). Heat inactivated lysate from 1000 HEK293
cells served as a negative control and telomerase positive
CD19q lymphoblasts (16) served as the positive control.
Quantitative levels of TA were obtained from cellular
proteins of 1000 cells, serial dilutions of cellular proteins or
supernatant.
Tissue culture
Cell lines (Jurkat, Daudi, Karpas, K562, L540 and HEK293)
were purchased from ATCC (Wesel, Germany) and grown in
RPMI 1640 (supplemented with 10% fetal calf serum, gluta-
mine and penicillin and streptomycin, all from Gibco, Karls-
ruhe, Germany). Lines were maintained in a 378C, 5% CO2
atmosphere and divided splitted twice per week.
Statistical analyses
Graphs and statistical analyses were performed using
SigmaPlot (Version 7.0) and SigmaStat (Version 2.03; both
from SPSS Inc, Chicago, IL, USA). Repeated measure ANO-
VA was used for the analysis of TA at different time points
during the time delay experiment. Differences in TA from
cellular proteins or tissue culture supernatant were analysed
using the unpaired Student’s t-test. Correlation between
(telomerase-) elongated template and cycle number was
determined with linear regression analysis.
Results
TA determined by RQ-Trap assay
Serial dilutions of HEK293 cells were assayed for TA
to generate a standard curve for comparison with
other cell lines and clinical samples. The RQ-Trap
assay showed reproducible linearity from 1000 to 8
HEK293 cells w(Figure 1: R2s0.99, Figure 2 see online
Supplementary data)x.
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TA in Meningeosis neoplastica
To test our hypothesis that the RQ-Trap assay is
appropriate for clinical usage in the detection of
Meningeosis neoplastica, we have studied 111
patients during routine clinical CSF examination.
Diagnosis of Meningeosis neoplastica was estab-
lished cytologically in 15 cases by a local neuropa-
thologist (Table 1). All of these specimens had
detectable TA. A negative result in the RQ-Trap assay
correlated with non-malignant CSF in 96 patients.
However, one patient had a positive result without
clinical signs of Meningeosis neoplastica. This patient
was a 6-year-old male patient who was in clinical
remission with T-cell non-Hodgkin’s lymphoma (NHL)
and undergoing lumbar puncture for prophylactic
intrathecal methotrexate chemotherapy. Routinely
obtained CSF of this asymptomatic patient showed
an increased cell number (23/mL, upper normal value
3/mL) in combination with increased total protein
(2.53 g/L, upper normal value 0.45 g/L). There was no
clinical correlation to an infection or malignant con-
dition. Interestingly, the patient had received prophy-
lactic intrathecal chemotherapy 2 weeks prior to
lumbar puncture. The patient never developed menin-
geal involvement of his T-cell NHL and remains in
continuous complete remission. The sensitivity to
detect Meningeosis neoplastica with the RQ-Trap
assay was 100% (15/15 samples), whereas the speci-
ficity was 98.9% (95/96 samples). This resulted in a
positive predictive value (positive result for TA) of
0.94 and a negative predictive value of 1.0 for the
diagnosis Meningeosis neoplastica (Table 2). Further-
more, there was a highly significant association
between quantitative values of TA and a diagnosis of
Meningeosis neoplastica (Figure 3, p-0.001).
TA in supernatants
In order to potentially ease and more rapidly process
CSF specimens, we aimed to quantify TA in CSF
supernatant. TA was measured in eight patients with
Meningeosis neoplastica as well as from tissue cul-
ture supernatants from different cell lines (ns5).
None of the patients with clinically diagnosed Menin-
geosis neoplastica had detectable TA in their CSF
supernatant, despite traceable TA in corresponding
CSF cellular proteins (data not shown). In contrast,
4/5 tissue culture supernatants (Karpas, Jurkat, Daudi,
K562) showed detectable TA, proving that TA can be
measured directly in the supernatant (Figure 4).
Telomerase stability during the pre-analytic process
Finally, we examined the potential limitations of the
handling process of diagnostic CSF samples. Inacti-
vation of telomerase during any time delay in the
pre-analytic process may compromise the assay sen-
sitivity resulting in false negative results. We attempt-
ed to mimic delays in processing by incubating
HEK293 cells or their protein extracts from 0 h to
48 h at room temperature before measuring TA
(Figure 5). Stable TA levels were documented when
whole cells were incubated at room temperature,
whereas protein isolation extraction followed by incu-
bation at room temperature led to rapidly decreasing
TA levels (p-0.001).
Discussion
Meningeosis neoplastica is one of the most deleteri-
ous complications of neoplastic diseases requiring a
prompt and reliable diagnosis. To the best of our
knowledge, this is the first report to correlate TA
measured by RQ-Trap to the cytopathological diag-
nosis of Meningeosis neoplastica in a routine clinical
setting.
The test protocol requires only a small amount of
CSF (250 mL for CSF pleocytosis, depending on the
cell number) which can be obtained during routine
laboratory evaluation. The baseline sensitivity level of
8 malignant cells/1000 cells that we found is compar-
able to a recent report of Jakupciak et al. (24), who
reported a positive result of TA in 10/1000 A594 cells
with the RQ-Trap protocol. Notably, the RQ-Trap
protocol was about 10 times more sensitive com-
pared to an hTert mRNA quantification in the same
cells. Therefore, it will be of interest in future studies
to correlate results of TA to markers for minimal
residual disease in selected patients. With the rapid
and reliable assay presented in this study, 15/15
patients with Meningeosis neoplastica were identified
correctly. Furthermore, considering the high negative
predictive value of 1.0, this assay may serve as a
screening test for menigeosis neoplastica. However,
the results of this pilot study are preliminary due to
the limited patient number and require confirmation
using a larger population. Kleinschmidt-DeMasters et
al. (25) reported a sensitivity of 60% and specificity of
87% for the detection of Meningeosis neoplastica with
assessment of TA using conventional TRAP. The
increased sensitivity and specificity in our study may
be due to improvements in the assay system for the
detection of TA. Compared to conventional TA detec-
tion methods that rely on end time PCR (e.g., PCR-
ELISA or gel detection systems), the RQ-Trap assay
provides a greater linear range of analysis that is
more sensitive when compared to commercially
available PCR-ELISA applications (21). Moreover, with
the development of more specific primers to reduce
primer-dimers, the RQ-Trap provides a higher speci-
ficity. Finally, using RQ-Trap, the total analysis time is
reduced to -4 h with hands-on time -20 min. Also,
post-PCR carryover sample analysis errors are largely
reduced due to the closed tube application.
Our results show a correlation of TA with the pres-
ence of malignancy in CSF and are comparable to
studies using other body fluids (26–28). This indicates
that TA may be an easy to measure marker of
malignant cells from a broad spectrum of routine
diagnostic samples. However, there are limitations in
sensitivity and specificity depending on the sample
source. Attempts to detect TA in the CSF supernatant
failed for patients’ samples. However, tissue culture
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Table 2 Contingency table.
Meningeosis No
neoplastica, n Meningeosis
neoplastica, n
Telomerase activity, n 15 1
No telomerase activity, n 0 95
Sum, n 15 96
Figure 3 Relative telomerase activity (TA) in Meningeosis
neoplastica and from non-neoplastic CSF.
The level of TA is displayed in % as relative TA compared to
that of 1000 HEK293 cells and expressed as box plots, dis-
playing the median as horizontal lines and boxes as 25th and
75th percentile as well as whiskers indicating 10th and 90th
percentile. The real-time quantitative telomere repeat ampli-
fication protocol (RQ-Trap) assay for relative TA discriminat-
ed Meningeosis neoplastica from non-malignant conditions
(*p-0.001).
Figure 4 Telomerase activity (TA) in cellular proteins or
tissue culture supernatant.
Relative TA was quantified in cellular proteins (1000 cells) of
5 different malignant cell lines (Jurkat, Daudi, Karpas, K562
and L540) as well as in tissue culture supernatant. TA in tis-
sue culture supernatant was detectable in 4/5 cell lines at
lower levels compared to TA from cellular protein (ps0.03).
Figure 5 Stability of telomerase activity (TA).
TA measured from HEK293 cells during an incubation period
of up to 48 h at room temperature. White triangles show
stable TA in cellular proteins that were freshly isolated after
0 h, 1 h, 3 h, 10 h, 24 h and 48 h (ps0.89). In contrast, TA in
isolated proteins (protein isolation at 0 h) stored at room
temperature for 48 h declined rapidly (p-0.001) during the
incubation period. All values are expressed as mean"SEM.
supernatants of malignant cell lines showed repro-
ducibly increased levels of TA. This suggests that TA
in CSF supernatant may either be diluted by the phys-
iological CSF circulation (29), or our assay system
may not be sensitive enough to detect minimal
amounts of TA in CSF. Furthermore, extracellular TA
may be rapidly inactivated in a time dependent
manner if samples are not analysed immediately. This
was illustrated by the time-dependent decrease in TA
from protein extracts over time. Despite this, TA is
readily detectable in tumour cells from CSF for at
least 48 h at room temperature.
In conclusion, we demonstrate a fast, reliable and
robust method for the detection of TA in a clinical
pilot study for the detection of Meningeosis neoplas-
tica. Conceivably, RQ-Trap may function as a ‘‘CSF
quick test’’ to identify high-risk patients with lepto-
meningeal tumour involvement and may, thus, sup-
plement standard cytomorphological examination.
The assay is feasible for routine clinical usage and,
therefore, warrants further study in order to assess
the precise role of TA in CSF, as well as in the context
of repetitive testing during anti-tumour therapy.
Supplementary data associated with this article can be found
in the online version at: http://www.reference-global.com/
doi/suppl/10.1515/CCLM.2009.258.
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